寨卡病毒疫苗效力试验替代终点的评估
寨卡病毒感染孕妇可致小头症等出生缺陷(先天性寨卡综合征,CZS),但疫情后发病率大幅下降,CZS 为罕见结局,大规模 III 期试验难以实施。该研究通过模拟多种疫苗临床试验场景,比较 CZS 终点与每周、每两周或每月检测的 ZIKV 感染及实验室确诊的症状性寨卡病,评估各场景达到 80% 统计功效所需样本量和试验时长。结果显示 CZS 临床终点的可行性取决于模拟试验在季节性流行过程中的时机,因 CZS 风险随感染妊娠期变化。
要点
- CZS 终点可行性依赖试验在季节性流行中的时机,因风险随感染妊娠期变化。
- 低发病率下 CZS 作为罕见结局使大规模 III 期试验难以实施。
- 研究比较了 CZS 与检测发现的 ZIKV 感染及症状性寨卡病的样本量与时长。
核心结论
- CZS 临床终点的可行性取决于模拟临床试验在季节性流行过程中的时机。
- 设计针对致畸病原体的疫苗效力试验时需额外考虑感染妊娠期对结局风险的影响。
研究设计与样本
- 研究通过模拟多种疫苗临床试验场景进行评估。
- 比较 CZS 与每周、每两周或每月检测的 ZIKV 感染及实验室确诊的症状性寨卡病。
- 比较各场景达到 80% 统计功效所需样本量和试验时长。
主要发现
- CZS 风险随感染妊娠期变化,导致 CZS 终点可行性依赖试验时机。
- 低发病率下 CZS 为罕见结局,大规模 III 期试验可能不可行。
关键数值与推荐
- 以 80% 统计功效检测疫苗效力比较各场景所需样本量和试验时长。
- 替代终点包括每周、每两周或每月检测的 ZIKV 感染及实验室确诊的症状性寨卡病。
临床怎么用
- 设计寨卡疫苗效力试验时应考虑季节性流行时机对 CZS 终点可行性的影响。
- 低发病率时期可评估替代终点以减少样本量或缩短试验时长。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Zika virus (ZIKV) infection during pregnancy is associated with microcephaly and other birth defects, collectively termed Congenital Zika Syndrome (CZS). During the epidemic in 2015-16, ZIKV spread through the Americas and quickly joined the list of other known teratogenic pathogens, TORCH. Multiple ZIKV vaccines have been developed for protection of pregnant women and women of childbearing age. However, ZIKV infection incidence has since waned substantially, and adverse birth outcomes are rare outcomes of infection. Studying a vaccine's protective efficacy against CZS in a large phase III clinical trial may be infeasible in such times of low incidence. Should trials be initiated, researchers may resort to alternative clinical endpoints. In this study, we simulate a variety of vaccine clinical trial scenarios to evaluate the feasibility of the CZS endpoint in vaccine studies and compare CZS to other potential outcomes: ZIKV infection detected through weekly, biweekly, or monthly testing and laboratory-confirmed, symptomatic Zika Virus Disease. We compare the sample size required for 80% statistical power to detect vaccine efficacy and trial duration for each scenario. Our results show the feasibility of CZS clinical endpoints depends on the timing of simulated clinical trials in the course of a seasonal epidemic, due to CZS risk varying with trimester of infection. This result highlights additional considerations needed when designing vaccine efficacy trials of protection against teratogenic pathogens.
引用
- Mercaldo RA, Bellan SE. Evaluation of alternative endpoints for ZIKV vaccine efficacy trials. Vaccine. 2019. PMID: 30871928. doi:10.1016/j.vaccine.2019.02.066
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。